SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma Interventions: Drug: SCT-I10A; Drug: SCT510; Drug: Sorafenib 200mg Sponsor: Sinocelltech Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials